Industry News
Semaglutide: New Therapeutic Potentials
Semaglutide may have the potential to protect against cardiovascular disease, treat NAFLD, fight cancer, alleviate neurodegenerative diseases and reduce addictive behaviors, etc.
Bystander Effects of Antibody-Drug Conjug…
The bystander effect of ADC is expected to solve heterogeneous expression of target antigens (Ag) in metastatic tumor tissues.
List of GLP-1 Receptor Agonists for Diabe…
Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared. …
A Comprehensive Guide to ADC Payload Clas…
ADC payloads are critical components of the ADC structure, and their selection and design are crucial for achieving optimal therapeutic efficacy and minimizing toxicity.
Covalent PROTACs, An Emerging Protein Deg…
In recent years, a new technology that combines covalent inhibitors and PROTACs has emerged—covalent PROTAC technology, including reversible covalent and irreversible covalent PROTAC.
Multifunctional Peptides: Novel Direction…
The emerging technologies such as multifunctional peptides, binding peptides, peptide conjugates, oral peptides, long-acting, and delivery systems have greatly contributed to the prosperity o…
Peptide Drug Conjugates (PDCs): Novel Tar…
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics after ADCs, and their core advantages are enhanced cell permeability and improved drug selectivity. In recent y…
Innovative Treatments For Cervical Cancer…
In recent years, the emergence of targeted therapy and immunotherapy has brought new hope to patients with advanced cervical cancer. Currently, two targeted therapies and two immunotherapies …
Overview of Oligonucleotide Therapeutics …
To date, 15 oligonucleotide therapeutics have been approved by the U.S. Food and Drug Administration (FDA) .
Target And Clinical Trial Progress of ADC…
A total of 15 ADC drugs have been approved for hematological malignancies and solid tumors worldwide till now. In addition, there are currently more than 100 ADC candidates are in various sta…
sales@huatengusa.com
+86 0731 89916275